Reviews in Endocrine and Metabolic Disorders

, Volume 3, Issue 3, pp 243–256 | Cite as

Hormonal Replacement Therapy

Article
estrogen progestrins cardiovascular risk breast cancer risk cognition bone endometrial disease 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bongaarts J, Zimmer Z. Living arrangements of older adults in the developing world: An analysis of DHS household surveys. J Gerontol Soc Sci 2002;57B:5145-5147.Google Scholar
  2. 2.
    Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.Google Scholar
  3. 3.
    Colditz GA. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987;316:1105-1110.Google Scholar
  4. 4.
    Bush TL, Barrett-Connor E, Cowan LD, Wallace RB, Suchindran CM, Tyroler HA, Rifkind BM. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinic Program follow-up study. Circulation 1987;75:1102-1109.Google Scholar
  5. 5.
    Hulley S, Grady D, Bush T, Furberg C, Herrington O, Riggs B, Vittinghoff E. Heart and estrogen/progestin replacement study (HERS) research group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-613.Google Scholar
  6. 6.
    Herrington DM, Reboussin DM, Bosnihan KB, Sharp PC, Shumaker SA, Snyder TE, Furber CD, Kowalchuk GJ, Stuckey TD, Rogers WJ, Givens DH, Waters D. Effects of estrogen replacement on progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-529.Google Scholar
  7. 7.
    Mosca L, Collins P. Hormone replacement therapy and cardiovascular disease: A statement for Healthcare professionals from the American Heart Association. Circulation 2001;104:499-503.Google Scholar
  8. 8.
    Mendelsohn ME, Karas RH. Editorial: The time has come to stop letting the HERS tale wag the dogma. Editorial: Circulation 2001;104:2256-2257.Google Scholar
  9. 9.
    Hendry D, Robertson J. A systematic review of the skeletal effects of estrogen therapy in postmenopausal women. I. An assessment of the quality of randomized trials published between 1977 and 1995. Climacteric 1998;1:92-111.Google Scholar
  10. 10.
    Groeneveld FP, Bareman FP, Barentsen R, Dokter HJ, Drogendijk AC, Hoes AW. Duration of hormonal replacement therapy in general practice; a follow-up study. Maturitas 1998;29(2):125-131.Google Scholar
  11. 11.
    Yen SSC, Martin PL, Burnier AM, Czekala NM, Greney MO, Jr., Callantine MR. Circulating estradiol, estrone and gondadotropin levels following the administration of orally active 17b-estradiol in postmenopausal women. J Clin Endocrinol Metab 1975;40:518-520.Google Scholar
  12. 12.
    Sitruk-Ware R. Pharmacology of estrogens. Different routes of administration, oral versus transdermal. In: Oettel M, Shillinger E, (eds). Handbook of Experimental Pharmacology, vol 135, Estrogen and Antiestrogens. Heidelberg: Springer Verlag, 1999;247-257.Google Scholar
  13. 13.
    Barnes RD, Lobo RA. Pharmacology of estrogens. In: Mishell DR, Jr., ed. Menopause Physiology and Pharmacology, Chicago Year Book Medical Publishers, 1987;301-315.Google Scholar
  14. 14.
    Gurpide E. Metabolic influences of the action of estrogens; therapeutic implications. Pediatrics 1978;62(Suppl.):1114-1120.Google Scholar
  15. 15.
    Clarck JH, Peck EJ, Jr. Female sex steroids, receptors and function. Monographs on Endocrinology. New York: Springer, 1979.Google Scholar
  16. 16.
    Stanczyk FZ, Shoupe D, Nunez V, Macias-Gonzales P, Vijod MA, Lobo A. A randomized comparison of non-oral estradiol delivery in postmenopausal women. Am J Obstet Gynecol 1988;159:1540-1546.Google Scholar
  17. 17.
    Mishell DR, Jr., Moore DE, Roy S, Brenner PF, Page MA. Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol and d-norgestrel. Am J Obstet Gynecol 1978;130:55-62.Google Scholar
  18. 18.
    Nash HA, Sanchez-Alvarez F, Mishell DR, Jr., Fraser IS, Maruo T, Harmon TM. Estradiol-delivering vaginal rings for hormone replacement therapy. Am J Obstet Gynecol 1999;181(6):1400-1406.Google Scholar
  19. 19.
    Rigg LA, Hermann H, Yen SSC. Absorption of estrogens from vaginal creams. N Engl J Med 1978;298:195-197.Google Scholar
  20. 20.
    Sitruk-Ware R, De Lignieres B, Basdevant A, Mauvais-Jarvis P. Absorption of percutaneous poestradiol in postmenopausal women. Maturitas 1980;2:207-211.Google Scholar
  21. 21.
    Marty JP, James M, Hajo N, Wepierre J, (eds). Percutaneous Absorption of Steroids. London: Academic Press, 1980;205-218.Google Scholar
  22. 22.
    Powers MS, Schenkel L, Darley PE, Good WR, Balestra JC, Place VA. Pharmacokinetics and pharmacodynamics of transdermal doasage forms of 17?-estradiol: comparison with conventional oral estrogen used for hormone replacement. Am J Obstet Gynecol 1985;152:1099-1106.Google Scholar
  23. 23.
    Erkkola RU, Hirvonen El, Juntunen K, Saastamoinen IA, Tuimala RI, Rinne R, Paakkari I. Comparison of transdermal to oral hormone replacement therapy. Eur Menopause J 1995;2:21-27.Google Scholar
  24. 24.
    Reginster JY, Donazzlo Y, Brion N, Lins R. Estradiol pharmacokinetics after transdermal application of patches to postmenopausal women: matrix versus reservoir patches. Climacteric 2000;3:168-175.Google Scholar
  25. 25.
    Studd J, Pornel B, Marton I, Bringer J, Varin C, Tsouderos Y, Christiansen C, for the Aerodiol Study Group. Efficacy and acceptability of Intanasal 17?-oestradiol for menopausal symptoms: randomized dose-response study. Lancet 1999;353:1574-1578.Google Scholar
  26. 26.
    Henzl MR, Edwards JA. Pharmacology of progestins: 17?-hydroxyprogesterone derivatives and progestins of the first and second generation. In: Sittruk-Ware R, Mishell DR, Jr. (eds), Progestins and Antiprogestins in Clinical Practice. New York: Marcel Dekker, 2000;101-132.Google Scholar
  27. 27.
    Sittruk-Ware R. Progestogens in HRT. New molecules. Menopause 2002;9:6-15.Google Scholar
  28. 28.
    Oettel M, Holz C. Hybrid Progestins: the example of Dienogest. Antiprogestins in Clinical Practice. New York: Marcel Dekker, 2000;163-178.Google Scholar
  29. 29.
    Oelkers W. Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects of the new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the Renin-Aldosterone System, body weight, blood pressure, glucose tolerance and lipid metabolism. J Clin Endocrinol Metab 1995;80:1816-1821.Google Scholar
  30. 30.
    Tuba Z, Bardin CW, Dancsi A, Francsics-Czinege E., Molnar C, Csorgei J, Falkay G, Koide SS, Kumar N, Sundaram K, Dukat-Abrok V, Balogh G. Synthesis and biological activity of a new progestogen, 16-methylene-17a-hydroxy-18-methyl-10-norpregn-4ene-3, 20-dione acetate. Steroids 2000;65:266-274.Google Scholar
  31. 31.
    Paris J, Thevenot R, Bonnet P, Granero M. The pharmacological profile of TX 066 (17a-acetoxy-6methyl-19-nor-4, 6-pregna-diene-3, 20-dione) a new oral progestative. Drug Res 1983;33:710-715.Google Scholar
  32. 32.
    Kumar N, Koide SS, Tsong YY, and Sundaram K. Nestorone®: a progestin with a unique pharmacological profile. Steroids 2000;65:629-636.Google Scholar
  33. 34.
    Hellman L, Yoshida K, Zumoff B, Levin J, Kream J and Fukushima DK. The effect of medroxyprogesterone acetate on the pituitary-adrenal axis. J Clin Endocrinol Metab 1976;42:912-917.Google Scholar
  34. 35.
    Duc I, Botella J, Bonnet P, Fraboul F, Delansorne R, Paris J. Antiandrogenic properties of nomegestrol acetate. Arzneim Forsch/Drug Res 1995;45(1):70-74.Google Scholar
  35. 36.
    Wilde MI, Balfour JA. Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations. Drugs 1995;50:364-395.Google Scholar
  36. 37.
    Shifren Jl, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP, Burki RE, Ginsburg ES, Rosen RC, Leiblum SR, Jones KP, Daugherty CA, Caramelli KE, Mazer NA. Transdermal testosterone in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682-688.Google Scholar
  37. 38.
    Kumar N, Didolkar AK, Monder C, Bardin CW, Sundaram K. The biological activity of 7?-Methyl-19-Nortestosterone is not amplified in male reproductive tract as is that of testosterone. Endocrinology 1992;130:3677-3683.Google Scholar
  38. 39.
    Pinkerton J, Santen R. Alternatives to the use of estrogen in postmenopausal women. Endocrine Rev 1999;20(3):308-320.Google Scholar
  39. 40.
    Burger HG. Selective oestrogen receptor modulators. Horm Res 2000;53(3):25-29.Google Scholar
  40. 41.
    1998 Consensus Statement: treatment of estrogen deficiency symptoms in women surviving breast cancer. J Clin Endocrinol Metab 2000;83:1993-2000.Google Scholar
  41. 42.
    Sitruk-Ware R, Thomas JL. Traitement local de l'atrophie urogénitale après la menopause. Praxis 1997;86:1245-1248.Google Scholar
  42. 43.
    Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy woth lower doses of CEE and medroxyprogesterone acetate. Fertil Steril 2001;75:1065-1075.Google Scholar
  43. 44.
    Notelovitz M, Cassel D, Hille D, Furst KW, Dain MP, Vandepol C, Skarinsky D. Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause. Am J Obstet Gynecol 2000;182(1 Pt 1):7-12.Google Scholar
  44. 45.
    Limouzin-Lamothe M, Mairon N, Joyce CRB, Gal ML. Quality of life after the menopause: Influence of hormonal replacement therapy. Am J Obstet Gynecol 1994;170(2):618-624.Google Scholar
  45. 46.
    Wiklund I, Karlberg J, Mattson LA. Quality of life and postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. Am J Obstet Gynecol 1993;168:824-830.Google Scholar
  46. 47.
    Burkman RT, Collins JA, Greene RA. Current perspectives on benefits and risks of hormone replacement therapy. Am J Obstet Gynecol 2001;185(2):S13-S23.Google Scholar
  47. 48.
    Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotowicz MA, Lane AW, Ludd HL, Caplan RH, Riggs BL. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992;117(1):1-9.Google Scholar
  48. 49.
    Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001;285(22):2891-2897.Google Scholar
  49. 50.
    Baron JA, Farahmand BY, Weiderpass E, Michaelsson K, Alberts A, Persson I, Ljunghall S. Cigarette smoking, alcohol consumption, and risk of hip fracture in women. Arch intern Med 2001;161(7):983-988.Google Scholar
  50. 51.
    Jensen J, Christensen C, Rodbro P. Cigarette smoking, serum estrogens, and bone loss during hormone replacement therapy early after menopause. N Engl J Med 1985;313:973-975.Google Scholar
  51. 52.
    Jensen J, Christiansen C. Effects of smoking serum lipoproteins and bone materials content during postmenopausal hormone replacement therapy. Am J Obstet Gynecol 1988;159:820-825.Google Scholar
  52. 53.
    Carlson LE, Sherwin BB. Higher levels of plasma estradiol and testosterone in healthy elderly men compared with age-matched women may protect aspects of explicit memory. Menopause 2000;7:168-177.Google Scholar
  53. 54.
    Mulnard RA, Cotman CW, Kawas C, Van Dyck CH, Sano M, Doody R. Estrogen replacement therapy for the treatment of mild to moderate Alzheimer disease: A randomized controlled trial. JAMA 2000;283:1007-1015.Google Scholar
  54. 55.
    Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340(23):1801-1811.Google Scholar
  55. 56.
    Rich-Edwards JW, Mason JE, Hennekens CH, Buring JE. The primary prevention of coronary heart disease in women. N Engl J Med 1995;332:1758-1766.Google Scholar
  56. 57.
    De Cleyn K, Buytaert P, Coppens M. Carbohydrate metabolism during hormonal substitution therapy. Maturitas 1989;11:235-242.Google Scholar
  57. 58.
    Pang SC, Greendale GA, Cedar MI, Cambone AC, Lozano K, Eggena P, Judd HL. Long term effects of transdermal estradiol with and without medroxyprogesterone acetate. Fertil Steril 1993;59:76-82.Google Scholar
  58. 59.
    The writing group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Intervention (PEPI) Trial. JAMA 1995;273:199-208.Google Scholar
  59. 60.
    Ylikorkala O, Cacciatore B, Paakkari I, Tikkanen MJ, Viinikka L, Toivonen J. The long term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin, and thromboxane. Fertil Steril 1998;69(5):883-888.Google Scholar
  60. 61.
    Davidson MH, Maki KC, Marx P, Maki AC, Cyrowski MS, Nanavati N, Arce JC. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women. Arch Intern Med 2000;160(21):3315-3325.Google Scholar
  61. 62.
    Williams JK, Cline JM, Honore EK, Delansorne R, Paris J. Coadministration of nomegestrol acetate does not diminish the beneficial effects of estradiol on coronary artery dilator responses in non human primates. Am J Obstet Gynecol 1998;179:1288-1294.Google Scholar
  62. 63.
    Shlipak M, Angeja BG, Go AS, Frederick PD, Canto JG, Grady D, for the National Registry of Myocardial Infarction-3 Investigators. Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women. Circulation 2001;104:2300-2304.Google Scholar
  63. 64.
    Perez-Gutthann S, Garcia-Rodriguez LA, Castelsague J, Duque-Oliart A. A population based case-control study. HRT and the risk of venous thromboembolic event. BMJ 1997;314:796-800.Google Scholar
  64. 65.
    Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001;285:1460-1465.Google Scholar
  65. 66.
    Coughlin SS, Giustozzi A, Smith SJ, Lee NC. A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol 2000;53:367-375.Google Scholar
  66. 67.
    Gray L, Christerpherson W, Hoover R. Estrogens and endometrial carcinoma. J Am Coll Obstet Gynecol 1977;49:385-389.Google Scholar
  67. 68.
    Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Controls 1999;10:253-260.Google Scholar
  68. 69.
    LaVecchia C, Brinton L, McTiernan A. Menopause, hormone replacement therapy and cancer. Maturitas 2001;39:97-115.Google Scholar
  69. 70.
    Janne O, Kauppila A, Kontula K. Female steroid receptors in normal, hyperplastic and carcinomatous endometrium. The relationship to serum steroid hormones and gonadotropins and changes during medoxyprogesterone acetate administration. Int J Cancer 1979;24:545.Google Scholar
  70. 71.
    Woodruff D, Pickar JH. Incidence of endometrial hyperplasia in post-menopausal women taking conjugated estrogens (Premarin) with medroxy progesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 1994;170:1213-1223.Google Scholar
  71. 72.
    Beresford SAA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997;349:458-461.Google Scholar
  72. 73.
    Archer D, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol 1994;83:686-692.Google Scholar
  73. 74.
    AinMelk Y. Comparison of two continuous combined estrogen progestogen regimen in postmenopausal women: a randomized trial. Fertil Steril 1996;66:962-968.Google Scholar
  74. 75.
    Ödmark IS, Jonsson B, Bäckström T. Bleeding patterns in postmenopausal women using continuous combination hormone replacement therapy with conjugated estrogen and medroxyprogesterone acetate or with 17?-estradiol and norethindrone acetate. Am J Obstet Gynecol 2001;184:1131-1138.Google Scholar
  75. 76.
    Langer RD, Pierce JJ, O'Hanlan KA, Johnson SR, Espeland MA, Trabal JF, Barnabei VM, Merino MJ, Scully RE. The Post-menopausal Estrogen/Progestin Interventions Trial. Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. N Engl J Med 1997;337:1792-1798.Google Scholar
  76. 77.
    Collaborative group on hormonal factors in breast cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-1059.Google Scholar
  77. 78.
    Schairer C, Lubin J, Troisi R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-491.Google Scholar
  78. 79.
    Ross RK, Paganni-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-332.Google Scholar
  79. 80.
    Magnusson C, Baron JA, Correira N. Breast cancer risk following long term oestrogen and oestrogen-progestin replacement therapy. Int J Cancer 1999;31:339-344.Google Scholar
  80. 81.
    Catherino WH, Jeng MH, Jordan VC. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediate mechanism. Br J Cancer 1993;67:945-952.Google Scholar
  81. 82.
    Catherino WH, Jordan VC. Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity. J Steroid Biochem Mol Biol 1995;55:239-246.Google Scholar
  82. 83.
    Plu-Bureau G, Lê M, Sitruk-Ware, Thalabard JC, Mauvais-Jarvis P. Progestogen use and risk of breast cancer in a cohort study of premenopausal women with benign breast disease. Br J Cancer 1994;70:270-277.Google Scholar
  83. 84.
    Santen R, Pinkerton JV, McCartney C, Petroni GR. Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. J Clin Endocrinol Metab 2001;86:16-23.Google Scholar
  84. 85.
    Genazzani AR, Gadducci A, Gambacciani M. Controversial issues in climacteric medicine II: Hormone replacement therapy and cancer. Maturitas 2001;40:117-130.Google Scholar
  85. 86.
    Clinical Synthesis Panel on HRT. Hormonal replacement therapy. Lancet 1999;354:152-155.Google Scholar
  86. 87.
    Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, Selzer RH, Liu Cr CR, Li Ch CH, Azen SP: Estrogen in the prevention of atherosclerosis trial research group. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001 (Dec);135:939-953.Google Scholar
  87. 88.
    The North American Menopause Society. Achieving long-term continuance of menopausal ERT/HRT: Consensus opinion of the North American Menopause Society. Menopause 1998;5:69-76.Google Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  1. 1.Rockefeller University and Population CouncilNew YorkUSA

Personalised recommendations